Print Page  |  Close Window

SEC
10-Q
BIOTELEMETRY, INC. filed this Form 10-Q on 10/31/2018
Entire Document
 << Previous Page | Next Page >>


Sales and Marketing Expense
 
Three Months Ended
 
Change
(in thousands, except percentages)
September 30,
2018
 
September 30,
2017
 
$
 
%
Sales and marketing expense
$
10,120

 
$
9,719

 
$
401

 
4.1
%
Percentage of revenues
10.1
%
 
12.0
%
 
 
 
 
The increase in sales and marketing expense for the three months ended September 30, 2018 was due primarily to $0.3 million of additional expense for sales meetings.
Bad Debt Expense
 
Three Months Ended
 
Change
(in thousands, except percentages)
September 30,
2018
 
September 30,
2017
 
$
 
%
Bad debt expense
$
5,157

 
$
3,768

 
$
1,389

 
36.9
%
Percentage of revenues
5.2
%
 
4.7
%
 
 
 
 
The increase in bad debt expense for the three months ended September 30, 2018 was due primarily to the increased Healthcare revenue and the timing of the Healthcare collections. Bad debt expense in Research was minimal and is recorded on a specific account basis.
Research and Development Expense
 
Three Months Ended
 
Change
(in thousands, except percentages)
September 30,
2018
 
September 30,
2017
 
$
 
%
Research and development expense
$
2,429

 
$
3,277

 
$
(848
)
 
(25.9
)%
Percentage of revenues
2.4
%
 
4.0
%
 
 
 
 
Research and development expense for the three months ended September 30, 2018 decreased due primarily to $0.7 million of synergies related to the full-quarter impact of the integration of LifeWatch, as well as other cost savings initiatives.
Other Charges
 
Three Months Ended
 
Change
(in thousands, except percentages)
September 30,
2018
 
September 30,
2017
 
$
 
%
Other charges
$
1,330

 
$
8,152

 
$
(6,822
)
 
(83.7
)%
Percentage of revenues
1.3
%
 
10.1
%
 
 
 
 
Other charges for the three months ended September 30, 2018 were due primarily to the continued integration and restructuring activities related to the LifeWatch acquisition and patent litigation.
Other charges for the three months ended September 30, 2017 were due primarily to legal and professional fees, as well as severance costs, related to the LifeWatch acquisition, offset by the change in fair value of contingent consideration related to certain 2016 acquisitions.

35

 << Previous Page | Next Page >>